Health
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
WILMINGTON, Del., October 17, 2025--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS) versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with c
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/73c3abd5db8a65de243b45d7ba98d516"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ssR6qKN.G5w4aXzMQjAZwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/73c3abd5db8a65de243b45d7ba98d516","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QyRsDp9uGjyZuXV4ofEnDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/73c3abd5db8a65de243b45d7ba98d516","width":1181,"height":286}},"lazy":false},{"type":"text","content":"More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three years","length":107,"tagName":"p","attribs":{}},{"type":"text","content":"First and only perioperative immunotherapy approach to show survival benefit in this setting","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., October 17, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS) versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.","length":844,"tagName":"p"},{"type":"text","content":"These results will be presented today in a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (abstract #LBA81).","length":170,"tagName":"p"},{"type":"text","content":"In the final OS analysis, results showed the IMFINZI and FLOT perioperative regimen reduced the risk of death by 22% compared with chemotherapy alone (based on a ha...